Study guide
14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
Key Takeaways Explain This Topic AI
Mass casualty incident triage shifts clinical ethics from individual-centered care to utilitarian population survival, utilizing START (Respirations, Perfusion, Mental status) and SALT (Sort, Assess, Lifesaving Interventions, Triage) algorithms.
Chemical nerve agent exposure produces lethal cholinergic hyperstimulation managed by immediate decontamination, high-dose atropine (2 mg IM titrated to dry pulmonary secretions), pralidoxime (600 mg IM to reactivate acetylcholinesterase before aging), and benzodiazepines (CANA autoinjector) for seizures.
Hydroxocobalamin (Cyanokit 5 g IV over 15 minutes) is the first-line antidote for cyanide toxicity, binding cyanide into cyanocobalamin without causing methemoglobinemia, making it uniquely safe in smoke inhalation victims with concomitant carbon monoxide toxicity.
Biological threat agents require immediate countermeasure deployment: Inhalation Anthrax mandates 60-day oral prophylaxis (ciprofloxacin or doxycycline) or IV triple therapy plus antitoxin for active disease; Botulism requires heptavalent antitoxin (HBAT); Pneumonic Plague requires aminoglycosides or fluoroquinolones.
Radiological protection relies on Potassium Iodide (KI 130 mg PO) for immediate thyroid blockade against iodine-131, Prussian blue for gastrointestinal trapping of cesium-137 and thallium, and Ca-/Zn-DTPA for chelation of internal plutonium, americium, and curium contamination.
Last updated: October 2026
14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around emergency medicine pharmacotherapy principles tested on clinical specialist certification examinations.
Mass Casualty Incidents (MCIs) & Disaster Triage Frameworks
A Mass Casualty Incident (MCI) occurs when the number, severity, and diversity of arriving casualties overwhelm the local emergency medical infrastructure, staffing, and pharmaceutical reserves. In everyday emergency practice, healthcare teams operate under an individual-centered ethical framework , deploying exhaustive resources to achieve optimal outcomes for every single patient. In an MCI, medical ethics fundamentally shift to a utilitarian population-based framework : doing the greatest good for the greatest number of viable casualties with the available resources.
The START Triage System (Adults)
The Simple Triage and Rapid Treatment (START) algorithm is the most widely adopted field and hospital-entry triage model. It systematically categorizes casualties into four color-coded operational designations in under 60 seconds per patient using three clinical assessments: Respirations , Perfusion , and Mental Status (RPM) . START DISASTER TRIAGE ALGORITHM
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Step 1: Initial Global Sorting │
- │ Direct all ambulatory casualties to walk to a designated secondary area. │
- │ All walking patients ──────────────────────────────────────────► GREEN (Minor)│
- └──────────────────────────────────────┬──────────────────────────────────────┘
- ▼
- Step 2: Evaluate Spontaneous Respirations
- │
- ┌───────────────────────┴───────────────────────┐
- ▼ APNEIC ▼ PRESENT
- ┌───────────────────────────────┐ ┌───────────────────────────────┐
- │ Reposition Upper Airway │ │ Respiratory Rate Check │
- │ Still Apneic ──► BLACK (Dead) │ │ > 30 breaths/min ──► RED (Imm)│
- │ Resumes Breathing ─► RED (Imm)│ │ < 30 breaths/min ──► Assess P │
- └───────────────────────────────┘ └───────────────┬───────────────┘
- ▼
- Step 3: Assess Perfusion
- │
- ┌───────────────────────────────┴───────────────┐
- ▼ ABSENT RADIAL / CAP REFILL > 2s ▼ PRESENT
- ┌───────────────────────────────┐ ┌───────────────┴───────────────┐
- │ Control Bleeding ──► RED (Imm)│ │ Step 4: Assess Mental Status │
- └───────────────────────────────┘ │ Cannot Follow Commands ─► RED │
- │ Follows Commands ──► YELLOW │
- └───────────────────────────────┘
- Color-Coded Triage Categories
RED (Immediate) : Critical, life-threatening injuries or physiological instability requiring immediate intervention within minutes to survive (e.g., tension pneumothorax, respiratory rate >30, signs of shock, uncontrolled arterial bleeding). Highest treatment and transport priority.
YELLOW (Delayed) : Serious injuries requiring medical intervention within hours, but physiological status is currently stable without imminent threat to life or limb (e.g., stable long-bone fractures, large soft tissue lacerations without hemorrhagic shock, normal RPM parameters).
GREEN (Minor / Walking Wounded) : Ambulatory patients with minor abrasions, sprains, or contusions. Directed to remote treatment sectors to prevent crowding of acute resuscitation bays.
BLACK (Expectant / Deceased) : Patients who are deceased (apneic despite airway repositioning) or whose injuries are so catastrophic (e.g., 95% third-degree burns, open traumatic brain injury with extruded cerebral tissue) that survival is improbable given available medical resources during an active disaster. Provided palliative comfort care if resources permit.
The SALT Triage Framework
The SALT (Sort, Assess, Lifesaving Interventions, Triage/Treat) algorithm enhances START by incorporating early, rapid lifesaving interventions before assigning final triage status:
Global Sorting : Sort casualties into groups based on voice commands (1: walk to area [assessed third]; 2: wave or purposeful movement [assessed second]; 3: still or obvious life threat [assessed first]).
Lifesaving Interventions : Perform immediate, rapid interventions: apply tourniquet for catastrophic extremity hemorrhage, open airway (provide 2 rescue breaths for apneic pediatric patients), perform needle thoracostomy for tension pneumothorax, and administer immediate antidote auto-injectors (e.g., nerve agent antidotes).
Individual Triage : Assign category: Immediate (Red), Delayed (Yellow), Minimal (Green), Expectant (Gray), or Dead (Black).
Chemical Warfare Agents: Nerve Agents & Cyanide
Chemical threats represent high-velocity toxicological emergencies requiring immediate personal protective equipment (PPE Level C or B) and rapid empiric antidote administration.
Chemical Nerve Agents (Sarin, Soman, Tabun, VX)
Mechanism : Nerve agents are highly potent, organophosphate chemical compounds that irreversibly bind to and inhibit the enzyme acetylcholinesterase (AChE) . This leads to massive, uncontrolled accumulation of acetylcholine at postganglionic parasympathetic muscarinic receptors, skeletal neuromuscular nicotinic junctions, and central nervous system synapses.
Clinical Presentation : Severe cholinergic crisis remembered by SLUDGEM (Salivation, Lacrimation, Urination, Defecation, Gastrointestinal distress, Emesis, Miosis) or DUMBELS (Defecation, Urination, Miosis, Bradycardia/Bronchorrhea/Bronchospasm, Emesis, Lacrimation, Salivation). The primary cause of death is the "Killer B's": Bronchorrhea , Bronchospasm , and severe Bradycardia , compounded by diaphragmatic muscle paralysis and central apnea.
Mark I Autoinjector Kit / DuoDote :
Atropine (2 mg autoinjector) : A competitive muscarinic receptor antagonist that crosses the blood-brain barrier. It dries copious bronchial secretions, relieves severe bronchoconstriction, and restores heart rate. Administration Endpoint : Atropine is titrated aggressively until pulmonary secretions are completely dry and airway resistance clears ("atropinization"). Heart rate and pupil size are unreliable endpoints. Note: Atropine has zero activity at nicotinic receptors and therefore does not reverse skeletal muscle weakness or diaphragmatic paralysis.
Pralidoxime Chloride (2-PAM, 600 mg autoinjector) : A nucleophilic oxime that uncouples the organophosphate molecule from acetylcholinesterase, reactivating the enzyme. It acts primarily at nicotinic junctions to restore skeletal muscle strength and reverse diaphragmatic paralysis. The Aging Phenomenon : Once the chemical bond between the nerve agent and acetylcholinesterase undergoes covalent dealkylation ("aging"), 2-PAM can no longer reactivate the enzyme. Soman ages within 2 minutes ; sarin ages in ~5 hours; VX ages in ~40 hours. Thus, 2-PAM must be administered immediately upon exposure.
CANA (Convulsive Antidote, Nerve Agent) :
Contains Diazepam 10 mg autoinjector (or Midazolam 10 mg autoinjector ). Nerve agent toxicity triggers severe, continuous status epilepticus driven by excessive central cholinergic and glutamatergic firing. Conventional anticonvulsants (phenytoin) are completely ineffective. High-dose GABA-A receptor agonists (benzodiazepines) must be administered immediately with the first dose of atropine/2-PAM to prevent permanent excitotoxic cerebral necrosis.
Cyanide Mass Casualty
Mechanism : Cyanide (hydrogen cyanide gas, potassium cyanide) rapidly binds with high affinity to the ferric iron (Fe3+) in cytochrome c oxidase (complex IV) of the mitochondrial electron transport chain. This halts oxidative phosphorylation, arrests cellular aerobic respiration, and shifts cellular metabolism to anaerobic glycolysis, causing profound lactic acid generation.
Clinical Presentation : Rapid onset of headache, confusion, seizures, coma, respiratory arrest, cardiovascular collapse, and severe metabolic acidosis with an elevated serum lactate (>8 to 10 mmol/L). Because tissues cannot extract oxygen from arterial blood, venous blood remains fully oxygenated, producing a bright red appearance of venous blood and high central venous oxygen saturation (SvO2 >85-90%).
Hydroxocobalamin (Cyanokit 5 g IV over 15 minutes) :
First-Line Antidote : Hydroxocobalamin contains a central cobalt atom that binds cyanide with higher affinity than cytochrome oxidase, forming non-toxic cyanocobalamin (vitamin B12) , which is safely eliminated in the urine. A second 5 g infusion may be administered over 15 minutes to 2 hours for refractory shock (total 10 g).
Safety in Smoke Inhalation : Hydroxocobalamin does not induce methemoglobinemia . It is completely safe to administer to victims of structural fires where concurrent carbon monoxide (CO) poisoning and carboxyhemoglobinemia are suspected. (Adverse effects: reddish skin and mucosal discoloration, chromaturia, transient hypertension).
Comparison with Sodium Nitrite : Traditional cyanide antidote kits contain sodium nitrite and sodium thiosulfate. Sodium nitrite oxidizes hemoglobin to methemoglobin (Fe3+), which binds cyanide to form cyanmethemoglobin. Sodium nitrite is contraindicated in smoke inhalation victims because methemoglobinemia further decreases oxygen-carrying capacity in patients with co-existing carboxyhemoglobinemia, precipitating fatal cellular hypoxia.
Biological Threat Agents: Anthrax, Botulism & Plague
Biological weapons utilize pathogenic microorganisms or toxins deliberately disseminated to cause widespread disease, panic, and societal disruption.
Inhalation Anthrax ( Bacillus anthracis )
Microbiology & Pathophysiology : Bacillus anthracis is a Gram-positive, spore-forming, rod-shaped bacterium. Inhaled spores are engulfed by pulmonary alveolar macrophages and transported to mediastinal lymph nodes, where they germinate into vegetative bacilli and produce lethal toxin and edema toxin. This causes severe, necrotizing hemorrhagic mediastinitis, non-cardiogenic pulmonary edema, and refractory septic shock.
Chest Radiograph Hallmark : Marked widening of the mediastinum and bilateral pleural effusions without parenchymal infiltrates.
Post-Exposure Prophylaxis (PEP) : Inhaled spores can remain dormant in lung parenchyma for months. PEP requires a continuous 60-day oral course :
Ciprofloxacin 500 mg PO every 12 hours, OR
Doxycycline 100 mg PO every 12 hours.
Active Systemic Disease Regimen :
Must utilize triple intravenous antimicrobial therapy: at least two bactericidal agents with distinct mechanisms plus one protein-synthesis inhibitor to shut down toxin production:
Agent 1 (Bactericidal) : Ciprofloxacin 400 mg IV every 8 hours (or Levofloxacin 750 mg IV q24h).
Agent 2 (Bactericidal) : Meropenem 2 g IV every 8 hours (extended infusion).
Agent 3 (Protein Synthesis Inhibitor) : Clindamycin 900 mg IV every 8 hours OR Linezolid 600 mg IV every 12 hours.
Antitoxin Therapy : Add monoclonal antitoxins targeting protective antigen: Raxibacumab , Obiltoxaximab , or Anthrax Immune Globulin Intravenous (AIGIV).
Botulism ( Clostridium botulinum )
Pathophysiology : Clostridium botulinum neurotoxin is the most lethal biological toxin known. The toxin cleaves SNARE proteins (synaptobrevin, SNAP-25, syntaxin) in presynaptic motor nerve terminals, permanently blocking the vesicular release of acetylcholine at neuromuscular junctions.
Clinical Presentation : Symmetric, descending, flaccid paralysis that begins with cranial nerve deficits ( the 4 D's : Diplopia, Dysarthria, Dysphonia, Dysphagia; plus ptosis and blurred vision) and progresses downward to the upper extremities, diaphragm, and lower extremities. Mentation and sensory exam remain entirely intact ; fever is characteristically absent.
Antidote Pharmacotherapy :
Heptavalent Botulinum Antitoxin (HBAT) : Contains equine-derived antibody fragments neutralizing toxin serotypes A, B, C, D, E, F, and G. HBAT neutralizes only unbound circulating neurotoxin in the bloodstream; it cannot reverse paralysis once toxin has internalized into presynaptic nerve terminals. Early administration arrests progression, but clinical recovery requires weeks to months for nerve terminals to regenerate synapses. Meticulous mechanical ventilatory support is the cornerstone of survival.
Pneumonic Plague ( Yersinia pestis )
Pathophysiology & Transmission : Yersinia pestis is a Gram-negative coccobacillus. Pneumonic plague is transmitted person-to-person via respiratory droplets, producing fulminant necrotizing pneumonia, hemoptysis, and overwhelming endotoxic shock.
Therapeutic Regimens :
First-line: Aminoglycosides— Streptomycin 1 g IM every 12 hours or Gentamicin 5 mg/kg IV once daily (or 1.7 mg/kg IV q8h).
Alternatives: Ciprofloxacin 400 mg IV every 8 hours or Levofloxacin 750 mg IV every 24 hours.
Post-Exposure Prophylaxis: Doxycycline 100 mg PO twice daily or Ciprofloxacin 500 mg PO twice daily for 7 days .
Radiological & Nuclear Countermeasures
Radiological mass casualties arise from nuclear detonations, reactor core melt-downs, or radiological dispersal devices ("dirty bombs"). Management involves immediate external physical decontamination (removing clothing removes ~90% of external contamination, followed by warm water washing) and administration of radioisotope-specific decorporation and blocking agents.
Radioisotope-Specific Decorporation & Blocking Agents
Potassium Iodide (KI) :
Target Radioisotope : Radioactive Iodine-131 (131I) and related isotopes released during nuclear fission reactions.
Mechanism : Ingestion of non-radioactive potassium iodide floods the bloodstream, saturating the thyroid sodium-iodide symporter (NIS). This competitively blocks the thyroid uptake of inhaled or ingested radioactive iodine-131 by >98%, preventing radiation-induced thyroid carcinoma.
Administration Dosing :
Adults and adolescents >68 kg: 130 mg PO once daily .
Children 3 to 18 years (<68 kg): 65 mg PO once daily .
Infants 1 month to 3 years: 32 mg PO once daily .
Neonates (birth to 1 month): 16 mg PO single dose .
Timing & Limitations : KI must be administered prior to or immediately following exposure (ideally within 2 to 4 hours; minimal protective efficacy after 24 hours). Crucial Clinical Point : Potassium iodide protects exclusively against thyroid uptake of radioactive iodine. It provides zero protection against any other radioisotope (e.g., cesium, strontium, plutonium) and zero protection against external whole-body gamma or neutron radiation .
Prussian Blue (Insoluble Ferric Hexacyanoferrate, Radiogardase) :
Target Radioisotopes : Cesium-137 (137Cs) and non-radioactive or radioactive Thallium (201Tl) .
Mechanism : Taken orally, Prussian blue acts as an ion exchanger in the gastrointestinal tract, binding cesium and thallium in the intestinal lumen to form insoluble crystal complexes. This interrupts enterohepatic recirculation and accelerates fecal excretion, reducing the biological half-life of cesium-137 from ~110 days to ~30 days.
Dosing : 3 g PO three times daily (adults); 1 g PO three times daily (children 2 to 12 years).
DTPA (Diethylenetriaminepentaacetic Acid) :
Target Radioisotopes : Internal contamination with transuranic actinides: Plutonium (Pu) , Americium (Am) , and Curium (Cm) .
Mechanism : DTPA forms stable, water-soluble coordination chelates with transuranic actinides, which are then rapidly excreted by glomerular filtration in the urine.
Calcium-DTPA (Ca-DTPA) : 1 g IV or nebulized inhalation . Far more effective than Zn-DTPA when administered within the first 24 hours post-contamination.
Zinc-DTPA (Zn-DTPA) : 1 g IV or nebulized inhalation . Used for maintenance chelation therapy after the initial 24 hours, or as the initial agent in pregnant patients (Ca-DTPA causes depletion of essential endogenous zinc and manganese minerals and is teratogenic with prolonged administration, whereas Zn-DTPA is significantly safer for prolonged use).
CBRNE Antidote & Countermeasure Matrix
CBRNE Threat Agent Mechanism of Toxicity First-Line Antidote / Countermeasure Dose, Route & Clinical Endpoints
Chemical Nerve Agents ( Sarin, Soman, VX ) Irreversible inhibition of acetylcholinesterase -> lethal cholinergic storm Atropine + Pralidoxime (2-PAM) + CANA (Diazepam/Midazolam) Atropine 2 mg IM q3-5m until dry lungs; 2-PAM 600 mg IM; Diazepam 10 mg autoinjector for seizures
Cyanide ( Hydrogen Cyanide Gas ) Inhibits cytochrome c oxidase (complex IV) -> blocks aerobic ATP Hydroxocobalamin (Cyanokit) 5 g IV over 15 min (repeatable to 10 g); safe in smoke inhalation with concurrent CO poisoning
Inhalation Anthrax ( Bacillus anthracis ) Lethal & edema toxins -> hemorrhagic mediastinitis & shock Ciprofloxacin + Meropenem + Clindamycin/Linezolid + Antitoxin Triple IV antibiotics + Raxibacumab/Obiltoxaximab; 60-day oral Cipro or Doxy for post-exposure prophylaxis
Botulism ( Clostridium botulinum ) Cleaves presynaptic SNARE proteins -> blocks ACh exocytosis Heptavalent Botulinum Antitoxin (HBAT) 1 vial IV infusion; neutralizes unbound circulating toxin; supportive mechanical ventilation
Pneumonic Plague ( Yersinia pestis ) Necrotizing pneumonia & endotoxic shock via droplet spread Gentamicin or Streptomycin ; alt: Ciprofloxacin Gentamicin 5 mg/kg IV q24h; PEP: Doxycycline 100 mg PO BID or Ciprofloxacin 500 mg PO BID x 7d
Radioactive Iodine-131 ( Nuclear Fission Plume ) Thyroid accumulation via NIS symporter -> thyroid carcinoma Potassium Iodide (KI) 130 mg PO daily (adults); 65 mg (children); must give within 2-4h; protects thyroid exclusively
Cesium-137 / Thallium ( Radiological Dispersal ) Soft tissue distribution, bone marrow suppression Prussian Blue (Ferric Hexacyanoferrate) 3 g PO TID; binds ions in GI lumen to interrupt enterohepatic recirculation; eliminates in feces
Plutonium / Americium ( Transuranic Contamination ) Bone surface and liver deposition, osteosarcoma Ca-DTPA (initial 24h) then Zn-DTPA (maintenance) 1 g IV or nebulized inhalation; forms stable urinary chelates; Zn-DTPA is safer in pregnancy
Strategic National Stockpile (SNS) Architecture & Surge Logistics
The Strategic National Stockpile (SNS), managed by the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), maintains massive repositories of pharmaceuticals, medical countermeasures, vaccines, and airway equipment designed to protect the American public during major public health emergencies.
12-Hour Push Packages
Design & Deployment : 12-Hour Push Packages are 50-ton, pre-packaged, containerized caches of broad-spectrum antibiotics, chemical antidotes, IV fluid supplies, airway kits, and wound dressings strategically pre-positioned in climate-controlled warehouses across the United States. They are designed to be loaded onto cargo transport and arrive at any designated domestic airfield within 12 hours of a federal deployment decision .
Vendor-Managed Inventory (VMI) : Once the immediate push package is delivered, subsequent replenishment waves are supplied through Vendor-Managed Inventory (VMI) contracts, delivering specific pharmaceuticals matched to the identified biological or chemical threat.
The CHEMPACK Forward-Deployed Program
Because nerve agent poisoning produces death from respiratory arrest within minutes to hours, victims cannot wait for 12-Hour Push Packages to arrive from federal warehouses. The CDC established the CHEMPACK program —a nationwide network of forward-deployed, climate-controlled chemical antidote containers pre-positioned directly in local hospitals and emergency medical service (EMS) depots:
Hospital CHEMPACK Containers : Contain approximately 1,000 casualty treatments . Configured with a higher proportion of multi-dose vials (e.g., atropine vials, bulk pralidoxime, multi-dose midazolam) suited for sustained inpatient care, ventilator beds, and continuous bedside medical resuscitation.
EMS CHEMPACK Containers : Contain approximately 450 casualty treatments . Configured with a higher proportion of prefilled autoinjectors (Mark I / DuoDote, CANA diazepam autoinjectors) for immediate, rapid administration in the warm zone, triage sectors, and initial field resuscitation.
Deployment Authority : CHEMPACK containers are secured with continuous remote temperature-monitoring sensors and electronic seal alarms. Local hospital incident commanders, emergency physicians, or emergency medical directors hold immediate legal authority to break container seals and release antidotes without waiting for federal approval whenever an organophosphate or nerve agent mass exposure is confirmed.
ED Operational Surge Capacity: The "4 S's"
To rapidly accommodate massive casualty inflows, emergency departments utilize the established "4 S's" disaster framework:
Staff : Mobilizing off-duty clinical personnel, activating physician and nursing labor pools, assigning emergency pharmacists to bedside antidote staging areas, and shifting to altered standards of care.
Stuff : Ensuring immediate access to disaster supply carts, personal protective equipment (PPE), mechanical ventilators, chest tubes, and rapid infusion devices; inventorying existing on-hand antidotes while requesting CHEMPACK container unsealing.
Space : Rapidly converting outpatient clinics, post-anesthesia care units (PACU), and hallway corridors into acute treatment bays; erecting external decontamination tents and triage sorting pavilions outside the physical ED entrance to prevent facility contamination.
Systems : Activating the Hospital Incident Command System (HICS), establishing clear incident command roles, transitioning electronic health records to disaster documentation modes, and coordinating real-time regional communications through regional healthcare disaster coalitions.